File Download
  Links for fulltext
     (May Require Subscription)

Conference Paper: D-enantiomeric antimicrobial peptides as antibacterial agent against drug-resistant Mycobacterium tuberculosis

TitleD-enantiomeric antimicrobial peptides as antibacterial agent against drug-resistant Mycobacterium tuberculosis
Authors
KeywordsPharmacy and pharmacology environmental studies
Toxicology and environmental safety
Issue Date2014
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO
Citation
The 17th World Congress of Basic and Clinical Pharmacology (WCP 2014), Cape Town, South Africa, 13-18 July 2014. In Basic & Clinical Pharmacology & Toxicology, 2014, v. 115 suppl. s1, p. 225-226, abstract no. 733 How to Cite?
AbstractBACKGROUND: Tuberculosis (TB) control efforts have taken on increased urgency due to the emergence of multidrug-resistance (MDR) and extensive drug-resistant (XDR) TB. Effective antibacterial therapeutics are desperately needed to combat the drug resistant TB. Antimicrobial peptides (AMPs) have the ability to target microbial pathogens within eukaryotic cells. In the present study, we investigated the activity of a family of structurally related D-enantiomeric AMPs (D-LAK peptides) against clinical isolates of MDR-TB and XDR-TB. Methods: The antibacterial activity of six D-LAK peptides (with different hydrophobicity and structural conformation) were tested against clinical isolates of drug susceptible, MDR and XDR Mycobacterium tuberculosis (Mtb) using broth micro-dilution assay in 96 well plates. The cytotoxicity of the D-LAK peptides on human macrophage-like cells (THP-1) was examined by lactate dehydrogenase (LDH) and 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) (MTT) assay. In addition, the effect of combining D-LAK peptides with isoniazid was also assessed against MDR-TB. RESULTS: All the D-LAK peptides tested could successfully inhibit the growth of Mtb in vitro to a certain extent and this was similarly effective against MDR and XDR strains. D-LAK peptides effectively broke down the heavy clumping of mycobacteria, consistent with a ‘detergent-like effect’ that could reduce the hydrophobic interactions between the highly lipidic cell walls of the mycobacteria, preventing bacteria cell aggregation. D-LAK peptides could not eradicate Mtb at non-toxic concentration, however they were effective as adjunct agent at low concentration to potentiate the efficacy of isoniazid against drug-resistant Mtb without inducing cytotoxicity to mammalian cells, possibly by facilitating the access of isoniazid into the mycobacteria by increasing the surface permeability of the pathogen. CONCLUSIONS: We have identified that out of the six tested D-LAK peptides, D-LAK120-A is the optimal peptide within the family based on the balance between anti-TB activity and the low cytotoxicity towards mammalian cells. Although D-LAK peptides alone may not be sufficiently potent at their nontoxic concentrations as anti-TB agent, they could be used as adjunct agent to improve the efficacy of the existing antibiotics against drug-resistant TB.
DescriptionSession - Drugs for Infectious Disease
This journal suppl. entitled: Special Issue: Abstracts of the 17th World Congress of Basic and Clinical Pharmacology ... 2014
Persistent Identifierhttp://hdl.handle.net/10722/201345
ISSN
2015 Impact Factor: 3.097
2015 SCImago Journal Rankings: 0.539

 

DC FieldValueLanguage
dc.contributor.authorLam, Jen_US
dc.contributor.authorLan, Yen_US
dc.contributor.authorMason, Jen_US
dc.date.accessioned2014-08-21T07:24:50Z-
dc.date.available2014-08-21T07:24:50Z-
dc.date.issued2014en_US
dc.identifier.citationThe 17th World Congress of Basic and Clinical Pharmacology (WCP 2014), Cape Town, South Africa, 13-18 July 2014. In Basic & Clinical Pharmacology & Toxicology, 2014, v. 115 suppl. s1, p. 225-226, abstract no. 733en_US
dc.identifier.issn1742-7835-
dc.identifier.urihttp://hdl.handle.net/10722/201345-
dc.descriptionSession - Drugs for Infectious Disease-
dc.descriptionThis journal suppl. entitled: Special Issue: Abstracts of the 17th World Congress of Basic and Clinical Pharmacology ... 2014-
dc.description.abstractBACKGROUND: Tuberculosis (TB) control efforts have taken on increased urgency due to the emergence of multidrug-resistance (MDR) and extensive drug-resistant (XDR) TB. Effective antibacterial therapeutics are desperately needed to combat the drug resistant TB. Antimicrobial peptides (AMPs) have the ability to target microbial pathogens within eukaryotic cells. In the present study, we investigated the activity of a family of structurally related D-enantiomeric AMPs (D-LAK peptides) against clinical isolates of MDR-TB and XDR-TB. Methods: The antibacterial activity of six D-LAK peptides (with different hydrophobicity and structural conformation) were tested against clinical isolates of drug susceptible, MDR and XDR Mycobacterium tuberculosis (Mtb) using broth micro-dilution assay in 96 well plates. The cytotoxicity of the D-LAK peptides on human macrophage-like cells (THP-1) was examined by lactate dehydrogenase (LDH) and 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) (MTT) assay. In addition, the effect of combining D-LAK peptides with isoniazid was also assessed against MDR-TB. RESULTS: All the D-LAK peptides tested could successfully inhibit the growth of Mtb in vitro to a certain extent and this was similarly effective against MDR and XDR strains. D-LAK peptides effectively broke down the heavy clumping of mycobacteria, consistent with a ‘detergent-like effect’ that could reduce the hydrophobic interactions between the highly lipidic cell walls of the mycobacteria, preventing bacteria cell aggregation. D-LAK peptides could not eradicate Mtb at non-toxic concentration, however they were effective as adjunct agent at low concentration to potentiate the efficacy of isoniazid against drug-resistant Mtb without inducing cytotoxicity to mammalian cells, possibly by facilitating the access of isoniazid into the mycobacteria by increasing the surface permeability of the pathogen. CONCLUSIONS: We have identified that out of the six tested D-LAK peptides, D-LAK120-A is the optimal peptide within the family based on the balance between anti-TB activity and the low cytotoxicity towards mammalian cells. Although D-LAK peptides alone may not be sufficiently potent at their nontoxic concentrations as anti-TB agent, they could be used as adjunct agent to improve the efficacy of the existing antibiotics against drug-resistant TB.-
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO-
dc.relation.ispartofBasic & Clinical Pharmacology & Toxicologyen_US
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectPharmacy and pharmacology environmental studies-
dc.subjectToxicology and environmental safety-
dc.titleD-enantiomeric antimicrobial peptides as antibacterial agent against drug-resistant Mycobacterium tuberculosisen_US
dc.typeConference_Paperen_US
dc.identifier.emailLam, J: jkwlam@hku.hken_US
dc.identifier.authorityLam, J=rp01346en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/bcpt.12259_6-
dc.identifier.hkuros233296en_US
dc.identifier.volume115-
dc.identifier.issuesuppl. s1-
dc.identifier.spage225-
dc.identifier.epage226-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats